Hans Peter Grimm

Title: The Innovations of Hans Peter Grimm

Introduction

Hans Peter Grimm is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of therapeutic agents, particularly in the design of dosage regimens. His work focuses on optimizing treatment protocols for patients requiring targeted therapies.

Latest Patents

Hans Peter Grimm holds a patent for "Materials and methods relating to dosage regimen design." This invention provides materials and methods for determining optimal dosage regimens for therapeutic agents. Specifically, it relates to dosage regimens for therapeutic agents capable of targeting the IL-2 receptor, particularly interleukin 2 (IL2)-based therapeutic agents. The methods outlined in the patent allow for the determination of general dosage regimens for new IL-2R targeted therapeutic agents, as well as the creation of specifically tailored dosage regimens for individuals undergoing treatment.

Career Highlights

Grimm is associated with Hoffmann-La Roche Inc., a leading company in the pharmaceutical industry. His work there has been instrumental in advancing therapeutic strategies that improve patient outcomes. With a focus on innovative solutions, he continues to contribute to the development of effective treatment methodologies.

Collaborations

Some of his notable coworkers include Benjamin Ribba and Volker Teichgräaeber. Their collaborative efforts have further enhanced the research and development initiatives within their field.

Conclusion

Hans Peter Grimm's contributions to the field of therapeutic agents and dosage regimen design highlight his innovative spirit and dedication to improving patient care. His patent and work at Hoffmann-La Roche Inc. exemplify the impact of targeted therapies in modern medicine.